Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Patient Linda Dzobiak (right) with Christin Whalen, RN, BSN, OCN
Researchers in the Gynecologic Oncology Program are exploring gynecologic cancers from a wide variety of scientific angles – from discoveries about the genes that cause tumors to develop and grow, to investigations of immunotherapies, to studies of ways
drugs can be combined to fight recurrent cancer.
Our basic scientists are looking at immune response through laboratory studies, creating laboratory models to study cancer resistance, and researching how to
exploit DNA repair defects. They are also exploring the genetic underpinnings of gynecologic cancers to find the mutations responsible for the disease. Our physician-scientists are focused on the development of new treatments for specific subtypes
of gynecologic cancers, including PARP inhibitors for BRCA-related high grade serous ovarian cancer, as well as methods for early detection of ovarian cancer.
We base our treatments on the latest scientific findings, and offer our patients the opportunity to participate in clinical trials of promising new treatments. Our clinical trial program is one of the largest and most active in the country, with more
than 20 open studies.
Many patients with gynecologic cancer – particularly ovarian – are diagnosed at a later stage when there are fewer conventional therapies. Many of our clinical trials offer new options for these patients, as we test new drugs as single agents or in combinations.
We pioneered many new treatments for gynecologic cancer (particularly ovarian) such as DNA repair treatments (including PARP inhibitors), immunotherapy, antibody drug conjugates, and anti-angiogenesis agents. Our leaders were involved in the research
leading to recent FDA approval of PARP inhibitors for recurrent ovarian cancer. We also have active trials studying strategies to overcome drug resistance, particularly to the platinum drugs often used in ovarian, endometrial, and cervical cancers.
Find a clinical trial
Appointments and Second Opinions